Life Sciences

  • May 13, 2026

    'Powerful' Risk For Women Using Talc, UC Prof Tells Jury

    An epidemiology professor at the University of California, San Francisco testified Wednesday in a Los Angeles bellwether trial over claims Johnson & Johnson's talc products caused deadly ovarian cancer in three women, saying there are multiple studies concluding the product increases the risk of the disease, including one finding a "very powerful" risk.

  • May 13, 2026

    3 NJ Employers Accused Of Pregnancy Discrimination

    A New Jersey hospital system, a laboratory company and a cleaning business must answer to allegations that they engaged in pregnancy discrimination in the workplace, state enforcers said this week.

  • May 13, 2026

    Walgreens Investors' Opioid Suit Is Time-Barred, Judge Says

    Pharmacy giant Walgreens no longer faces a proposed class action alleging it hurt investors when it disclosed opioid-related litigation losses after a Chicago federal judge found the claims were time-barred.

  • May 13, 2026

    Pa. Jury Finds Dispensary Subjected Fired Manager To Bias

    A Pennsylvania federal jury has awarded $203,500 to a dispensary employee who claimed Restore Integrative Wellness Center discriminated against him by terminating his employment after he went on leave to recover from injuries sustained in a car accident.

  • May 13, 2026

    Bayer, Buyers Get Final OK Of $4.85M Benzene Settlement

    A New Jersey federal judge on Wednesday gave final approval to a $4.85 million settlement to end claims against Bayer Healthcare LLC and others alleging that antifungal products were contaminated with benzene.

  • May 13, 2026

    Becton Hernia Mesh Antitrust Case Survives Dismissal

    A Pennsylvania federal court has refused to toss an antitrust case from Tela Bio Inc. accusing Becton Dickinson & Co. of abusing its dominant position in the hernia mesh market to block competing products.

  • May 13, 2026

    Conn. Doctor Asked To Pay $880K In IVF Fraud Dispute

    Two people who accused a reproductive endocrinologist of using his own sperm to impregnate their mothers have proposed that the doctor settle their suit against him for a total of $880,000, according to separate offers filed in Connecticut state court.

  • May 13, 2026

    Crowell & Moring Opens Minneapolis Office With 8 Lawyers

    Crowell & Moring LLP announced Wednesday that it is deepening its commitment to Minnesota by opening a new office in Minneapolis with a team of eight attorneys and said it's expecting more growth in the near future.

  • May 12, 2026

    DC Circ. Asked To Review EPA Incinerator Standards

    Environmental groups and a waste management association asked the D.C. Circuit to review the U.S. Environmental Protection Agency's March update to 20-year-old emissions standards for municipal waste incinerators.

  • May 12, 2026

    NJ Court Not Sure Bristol-Myers Investor Pled Negligence

    A New Jersey appellate panel on Tuesday pushed back on an investor's insistence that his complaint over Bristol-Myers Squibb's $74 billion acquisition of Celgene satisfied pleading standards for securities lawsuits, echoing a trial court judge's concern that claims of disclosure requirement shortfalls sounded more in fraud than negligence.

  • May 12, 2026

    Attys For Tufts Profs Didn't Blink In A Tenure Standoff

    When Jennifer Henricks and Kevin Peters first learned what was happening to tenured professors at Tufts University School of Medicine in Boston a few years ago, they knew that what was at stake involved more than just a dispute over the terms of a contract.

  • May 12, 2026

    AliveCor Wants Apple Health Monitor Patent Claims Tossed

    A medical software company has told a California federal court that claims in a pair of health monitoring patents Apple has accused it of infringing are actually invalid, saying they only cover abstract ideas without a technological innovation to save them.

  • May 12, 2026

    Elanco On Hook For Bulk Of $9M Flea & Tick Meds Deal

    Elanco Animal Health Inc. will pay $6.75 million while Petco, PetSmart, Chewy, Petsense and PetMeds are all on the hook for six-figure payouts under a settlement Tuesday resolving lawsuits accusing Elanco of paying pet supply retailers not to stock generic versions of its Advantix topical flea and tick prevention drug.

  • May 12, 2026

    Commerce Details Path To Discount For 100% Pharma Tariff

    The U.S. Department of Commerce released guidance for pharmaceutical companies looking to show they have made sufficient onshoring commitments to qualify for a discount on the 100% tariff on certain imported drugs coming this summer.

  • May 12, 2026

    Pa. Panel Struggles With Oversight Of $2.2B Opioid Fund

    A Pennsylvania appellate court on Tuesday questioned the system for distributing opioid companies' settlement money, after three counties and the city of Philadelphia said a review board unfairly disapproved their projects after the money was spent.

  • May 12, 2026

    Makary Out As FDA Commissioner, Trump Says

    U.S. Food and Drug Administration Commissioner Marty Makary is departing the agency, President Donald Trump confirmed on Tuesday, bringing to an end a tumultuous, one-year run as one of the nation's top health officials.

  • May 12, 2026

    SPAC, Investors Sue Aesthetics Co. Over Failed $250M Merger

    Viveon Health Acquisition Corp., a SPAC, and several investors have sued Townsgate Village Inc., formerly known as Suneva Medical Inc., in the Delaware Chancery Court, alleging that the aesthetics company strung them along in a failed $250 million special purpose acquisition company merger while secretly looking for another deal.

  • May 12, 2026

    FDA Leaders Outline How AI Is Shaping The Agency's Work

    The U.S. Food and Drug Administration is using generative artificial intelligence to help redact records before public release, summarize documents and evaluate scientific literature, federal officials said in a recent conference.

  • May 12, 2026

    Celgene Gets Final OK For $239M Deal, Atty Fees

    Investors in biopharmaceutical company Celgene Corp. have gotten a final nod for their $239 million deal to end proposed class claims that the company overstated commercial prospects for two of its drugs, and the investors' four-firm legal team will get fees and costs of nearly $57.3 million for their work on the case.

  • May 12, 2026

    Female Medtronic Manager's Firing Driven By Bias, Court Told

    Medtronic fired a longtime manager for disciplining a male subordinate and raising concerns about gender discrimination and retaliation, the worker told a Colorado state court.

  • May 11, 2026

    NJ Justices Back Coverage Exclusion Reservation Of Rights

    The New Jersey Supreme Court on Monday said an insurer doesn't waive its right to rely on a policy exclusion after initially defending a claim, backing Berkley Insurance Co. in a coverage dispute stemming from self-dealing suits against a pharmaceutical company and its chairman.

  • May 11, 2026

    Wash. Says Novartis Isn't Harmed By 340B Drug Pricing Law

    Washington is objecting to Novartis' attempt to block a state law that expands the discounts the drugmaker must provide under the federal 340B Drug Pricing Program, telling a federal court that worry about losing money doesn't constitute irreparable harm.

  • May 11, 2026

    Nestlé Sues To Unmask Amazon Sellers Of 'Stolen' Vitamins

    Nestlé Health Science U.S. filed a lawsuit in Washington state Friday in an effort to unmask "suspected bad actors" whom it accuses of illegally intercepting high volumes of nutritional supplements and funneling them to resellers on Amazon.com.

  • May 11, 2026

    Mead Johnson Heads To Trial In Ill. Baby Formula MDL

    An Illinois federal judge handling multidistrict litigation over baby formula that allegedly caused a serious abdominal condition in premature infants rejected Mead Johnson & Co. LLC's summary judgment bid in the fourth lawsuit parties had selected as an MDL tester case, teeing up the litigation's first trial.

  • May 11, 2026

    Beauty Tech Co. Execs Beat Investor Suit For Good

    A California federal judge Monday tossed a proposed class action accusing beauty technology firm Cutera and its executives of misleading investors about its acne treatment launch and financial results, finding the legal claims against the company were abandoned and discharged under its Chapter 11 plan.

Expert Analysis

  • Series

    Hosting Exchange Students Makes Me A Better Lawyer

    Author Photo

    Opening my home to foreign exchange students makes me a better lawyer not just because prioritizing visiting high schoolers forces me to hone my organization and time management skills but also because sharing the study-abroad experience with newcomers and locals reconnects me to my community, says Alison Lippa at Nicolaides Fink.

  • FDA's 2025 Enforcement Scorecard Highlights Data Focus

    Author Photo

    The U.S. Food and Drug Administration's increased enforcement activity in 2025 was driven by artificial intelligence and a focus on foreign manufacturers, necessitating proactive compliance strategies for an environment that is increasingly reliant on data, say attorneys at Reed Smith.

  • How A 1947 Tugboat Ruling May Shape Work Product In AI Era

    Author Photo

    Rapid advances in generative artificial intelligence test work-product principles first articulated in the U.S. Supreme Court’s nearly 80-year-old Hickman v. Taylor decision, as courts and ethics bodies confront whether disclosure of attorneys’ AI prompts and outputs would reveal their thought processes, say Larry Silver and Sasha Burton at Langsam Stevens.

  • Navigating Privilege Law Patchwork In Dual-Purpose Comms

    Author Photo

    Three years after the U.S. Supreme Court declined to resolve a circuit split in In re: Grand Jury, federal courts remain split as to when attorney-client privilege applies to dual-purpose legal and business communications, and understanding the fragmented landscape is essential for managing risks, say attorneys at Covington.

  • How AI Drafting Should Transform Patent Filing Strategies

    Author Photo

    As agentic artificial intelligence reduces the time and expense required to draft and file patents, companies should shift focus away from rationing drafting hours and more toward governing optionality, says Ian Schick at Paximal.

  • 5 Advertising Law Trends That Will Shape 2026

    Author Photo

    The legal landscape for advertisers will grow only more complex this year, with ongoing trends including a federal regulatory retreat, more aggressive action by the states, a focus on child privacy and expanded scrutiny of "natural" claims, say attorneys at Reed Smith.

  • Cannabis Industry Faces An Inflection Point This Year

    Author Photo

    Cannabis industry developments last year — from the passage of a new wholesale tax in Michigan, to an executive order accelerating the federal rescheduling process — presage a more mature phase of legalization this year, with hardening expectations and enforcement to come, says Alex Leonowicz at Howard & Howard.

  • Series

    Fly-Fishing Makes Me A Better Lawyer

    Author Photo

    Much like skilled attorneys, the best anglers prize preparation, presentation and patience while respecting their adversaries — both human and trout, says Rob Braverman at Braverman Greenspun.

  • 4 Ways GCs Can Manage Growing Service Of Process Volume

    Author Photo

    As automation and arbitration increase the volume of legal filings, in-house counsel must build scalable service of process systems that strengthen corporate governance and manage risk in real time, says Paul Mathews at Corporation Service Co.

  • Series

    The Law Firm Merger Diaries: Forming Measurable Ties

    Author Photo

    Relationship-building should begin as early as possible in a law firm merger, as intentional pathways to bringing people together drive collaboration, positive client response, engagements and growth, says Amie Colby at Troutman.

  • AG Watch: Va. Insulin Price Probe Signals Rising Scrutiny

    Author Photo

    Virginia Attorney General Jason Miyares' recent investigation into insulin manufacturers and pharmacy benefit managers for allegedly colluding to artificially inflate insulin prices reflects a broader trend to leverage consumer protection authority in high-impact healthcare matters, and the upcoming leadership change is unlikely to diminish scrutiny in this area, says Chuck Slemp at Cozen O'Connor.

  • FDA's AI Deployment Brings New Potential And Risks

    Author Photo

    The U.S. Food and Drug Administration's recent announcement about making agentic artificial intelligence tools available to agency employees may portend accelerated regulatory timelines and lower costs for drug companies and consumers, but potential errors and biases will necessitate additional safeguards, says Angela Silva at Lewis Brisbois.

  • 3 Key Takeaways From Planned Rescheduling Of Cannabis

    Author Photo

    An executive order reviving cannabis rescheduling represents a monumental change for the industry and, while the substance will remain illegal at the federal level, introduces several benefits, including improving state-legal cannabis operators' tax treatment, lowering the industry's legal risk profile, and leaving state-regulated markets largely intact, say attorneys at Dentons.

  • 6 Issues That May Follow The 340B Rebate Pilot Challenge

    Author Photo

    Though the Health Resources and Services Administration withdrew a pending case to reconsider the controversial 340B rebate pilot program, a number of crucial considerations remain, including the likelihood of a rework and questions about what that rework might look like, say attorneys at Spencer Fane.

  • 5 E-Discovery Predictions For 2026 And Beyond

    Author Photo

    2026 will likely be shaped by issues ranging from artificial intelligence regulatory turbulence to potential evidence rule changes, and e-discovery professionals will need to understand how to effectively guide the responsible and defensible adoption of emerging tools, while also ensuring effective safeguards, say attorneys at Littler.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.